In cancers, the exploitation of the noncanonical NF-κB pathway happens to resist apoptosis and promote an immunosuppressive tumor microenvironment, aiding tumor progression and treatment resistance [11,12,13]. This evidence concerns the gene NFKB1 and neoplasm.